


Attorney's Docket No. 011900-310
Application Serial No. 09/903,734
Page 2

## CLAIM SUMMARY DOCUMENT:

- 1. (Currently Amended) An A synergistic inhibitor composition of Helicobacter pylori adhesion in the gastrointestinal tract of a mammal consisting essentially of including humans, comprising (1) IgY antibodies obtained from at least one chicken egg laid by a hen which has been immunized with an antigenically effective amount of an isolated Helicobacter pylori urease, wherein said IgY antibodies are capable of specifically binding to the adhesion portion of Helicobacter pylori urease in the gastrointestinal tract of the mammal, and (2) at least one agent selected from H<sub>2</sub> blockers and proton pump inhibitors.
  - 2. (Original) The inhibitor composition according to Claim 1, wherein the IgY antibodies are isolated and purified antibodies.
  - 3. (Currently Amended) A pharmaceutical composition for preventing and/or treating a disease caused by or associated with *Helicobacter pylori* in a mammal consisting essentially of: including humans, comprising
  - a pharmaceutically effective amount of the a synergistic inhibitor composition consisting essentially of emprising (1) IgY antibodies obtained from at least one chicken egg laid by a hen which has been immunized with an antigenically effective amount of an isolated Helicobacter pylori urease in the gastrointestinal tract of the mammal, and (2) at least one agent selected from H<sub>2</sub> blockers and proton pump inhibitors; inhibitors; and

(05/03)





Attorney's Docket No. 011900-310 Application Serial No. 09/903,734 Page 3

a pharmaceutically acceptable carrier or diluent.

4. (Original) The pharmaceutical composition according to Claim 3, wherein the IgY antibodies are isolated and purified antibodies.

- 5. (Currently Amended) A method for inhibiting Helicobacter pylori adhesion in a mammal including humans, comprising orally administering to the mammal an inhibitor composition in an effective amount for inhibiting Helicobacter pylori adhesion, which composition emprises consists essentially of (1) IgY antibodies obtained from at least one chicken egg laid by a hen which has been immunized with an antigenically effective amount of an isolated Heliobactor pylori urease, wherein said IgY antibodies are capable of specifically binding to the adhesion portion of Helicobacter pylori urease in the gastrointestinal tract of the mammal, and (2) at least one agent selected from H2 blockers and proton pump inhibitors an inhibitor of gastric acid secretion.
- 6. (Currently Amended) A method for preventing and/or treating a disease caused by or associate with Hekocobacter pylori in a mammal including humans, comprising orally administering to the mammal an inhibitor composition in an effective amount for preventing or treating the disease, which composition eomprises consists essentially of (1) IgY antibodies obtained from at least one chicken egg laid by a hen which has been immunized with an antigenically effective amount of an isolated Heliobactor pylori urease,

(05/03)

P.09/11

Attorney's Docket No. 011900-310 Application Serial No. 09/903.734 Page 4

wherein said IgY antibodies are capable of specifically binding to the adhesion portion of Helicobacter pylori urease in the gastrointestinal tract of the mammal, and (2) at least one agent selected from H2 blockers and proton bump inhibitors an inhibitor of gastric acid secretion.

5 % (New) The inhibitor composition according to Claim 1, wherein the mammal is a human.

(New) The pharmaceutical composition according to Claim 3, wherein the mammal is a human.